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Abstract: Visceral leishmaniasis is hypoendemic in Medi-
terranean countries, where it is caused by the flagellate
protozoan Leishmania infantum. VL cases in this area account
for 5%–6% of the global burden. Cases of Leishmania/HIV
coinfection have been reported in the Mediterranean
region, mainly in France, Italy, Portugal, and Spain. Since
highly active antiretroviral therapy was introduced in 1997,
a marked decrease in the number of coinfected cases in
this region has been reported. The development of new
diagnostic methods to accurately identify level of parasit-
emia and the risk of relapse is one of the main challenges
in improving the treatment of coinfected patients. Clinical
trials in the Mediterranean region are needed to determine
the most adequate therapeutic options for Leishmania/HIV
patients as well as the indications and regimes for
secondary prophylaxis. This article reviews the epidemio-
logical, diagnostic, clinical, and therapeutic aspects of
Leishmania/HIV coinfection in the Mediterranean region.
Introduction
Visceral leishmaniasis (VL) is hypoendemic in the Mediterranean
region, where it is caused by the protozoan Leishmania infantum.
This parasite is transmitted by the bite of infected phlebotomine
female sandflies of the Phlebotomus genus and is maintained in a
zoonotic cycle, with dogs acting as the main reservoir [1].
Cases in the Mediterranean region only contribute to 5%–6%
of the global burden of VL, with an estimated annual incidence of
1,200–2,000 cases [2,3]. In Mediterranean countries, more than
27,000 new human immunodeficiency virus (HIV) infections were
diagnosed in 2012, corresponding to rates of 6.6 per 100,000
people [4].
Leishmania/HIV coinfection was an emergent problem in the
Mediterranean region during the 1990s, with cases occurring mainly
in four countries: France, Italy, Portugal, and Spain. Currently,
these countries still report most of the cases of coinfection in this
region [2,3], although the introduction of highly active antiretro-
viral therapy (HAART) in 1997 contributed to a marked decrease
in cases of coinfection (from 1,440 cases during the period of 1990–
1998 to 299 cases during 2001–2006, though this reduction was not
so marked in Portugal) [3].
Clinical manifestations of leishmaniasis in HIV-positive patients
in the Mediterranean region are not very different from those occur-
ring in immunocompetent patients, although atypical symptoms
and signs may occur [3].
Peripheral blood analysis by polymerase chain reaction (PCR) is
a highly sensitive and specific tool to detect the parasite in coin-
fected patients using a less invasive approach [5]. More recently,
the use of real-time PCR has been shown to be a suitable tool for
monitoring parasite load during the follow-up of coinfected patients,
helping to predict the risk of relapses after treatment [6,7].
Specific Leishmania-HIV interactions at the cellular level might
affect the course of infection for both pathogens. Visceral leish-
maniasis seems to hamper the immunological competence of HIV-
positive patients and heightens the increase in HIV load. Con-
comitant VL and HIV infection is characterized by significantly
lower cure rates, higher rates of drug toxicity, and higher relapse
and mortality rates when compared with HIV-negative VL patients.
The introduction of HAART in Europe has led to an improve-
ment in the quality of life of coinfected patients, reducing the
number of relapses as well as mortality, and has significantly
decreased the number of new cases of coinfection. Nevertheless, VL
relapses occur in patients on HAART despite increasing CD4+
counts and undetectable HIV loads [3,8]. Moreover, VL also seems
to hamper the immunological recovery of the HIV-positive patients
treated with HAART [9].
The major clinical trials on treatment and secondary prophylaxis
in coinfected patients have been carried out in southern European
countries. For VL/HIV-coinfected patients in the Mediterranean
area, amphotericin B (deoxycholate or the lipid or liposomal for-
mulations) is the first-line therapeutic option, followed by mainte-
nance therapy [10–12].
This article reviews the epidemiological, diagnostic, clinical, and
therapeutic aspects of Leishmania/HIV coinfection in the Medi-
terranean region.
Epidemiology of Visceral Leishmaniasis and HIV
Coinfection in the Mediterranean Region
Isoenzyme typing of L. infantum strains isolated from HIV
patients in the Mediterranean region shows a high level of poly-
morphism. Although most VL cases are caused by viscerotropic
zymodemes, other dermotropic or dermo-viscerotropic strains and
other new strains that have not been identified in HIV-negative
patients are known to affect coinfected patients [13,14].
L. infantum is transmitted by the bite of infected phlebotomine
female sandflies of the Phlebotomus genus and maintained in a
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zoonotic cycle, with dogs acting as the main reservoir [1]. Data on
Leishmania infections in other mammals are increasingly reported,
although their role in transmission has yet to be elucidated [15].
Wild carnivores such as the wolf (Canis lupus), the red fox (Vulpes
vulpes), the Egyptian mongoose (Herpests ichneumon), the genet
(Geneta geneta), the pine marten (Martes martes), and the Iberian
lynx (Lynx pardinus) have also been implicated in the maintenance
of L. infantum transmission. Recently, infected Iberian hares (Lepus
granatensis) have been associated with the ongoing outbreak in
Spain [16].
Xenodiagnosis studies performed in the Mediterranean region
have shown that L. infantum may develop in Phlebotomus perniciosus
when it feeds on VL/HIV-coinfected patients [17]. Transmission
may also occur through the sharing of contaminated syringes
among intravenous drug users [18]. Furthermore, it has been shown
that detection of parasitemia in peripheral blood samples by PCR is
much more frequent among HIV/VL-coinfected patients than in
non-HIV-infected patients with VL [19]. These data suggest that
HIV/VL-coinfected patients may be more infectious than non-
HIV-infected patients and that a simultaneous natural anthro-
ponotic cycle could be considered in the epidemiology of VL due
to L. infantum in HIV-coinfected patients [17]. In addition, L.
donovani, which is mainly associated with anthroponotic transmis-
sion, has recently been identified as the etiological agent in cases of
VL in Cyprus and Turkey [20].
Since the World Health Organization (WHO) discontinued its
database in 2006, there is no centralized system updating data
on VL/HIV. The last comprehensive information available was
updated in 2007 during a WHO consultative meeting in Addis
Ababa [21]. Since then, WHO has made efforts to set up a program
in selected areas of the European region [22,23]
Southern European countries are known hypoendemic areas for
leishmaniasis, with a calculated incidence of 0.4 cases per 100,000
inhabitants per year in the case of Spain. Previously, two-thirds of
patients were children, but after 1985 when the HIV pandemic
started, up to 70% of the patients were adults, reflecting the
pattern of HIV age risk groups [24]. The unexpectedly high rate
of VL/HIV coinfection in Europe, mainly in Spain (where 80% of
all cases notified to the WHO occurred [25]), indicate that HIV
infection is a risk factor associated with VL [26]. In order to
provide a population-based estimate of the burden of hospitaliza-
tion caused by leishmaniasis and coexisting Leishmania/HIV, the
Spanish Central Hospital Discharge Database (which includes
data for .95% of all hospitalized patients in the whole country)
was analyzed for the period 1997–2008. The prevalence of HIV-
positive patients in the general hospitalized population was 0.58%
[27], and the prevalence of HIV-positive patients among the 2,028
patients hospitalized with leishmaniasis was 37% [8]. Moreover, in
an ongoing outbreak in southwest Madrid, a region with around
500,000 inhabitants, an incidence of 22.2 cases per 100,000 habi-
tants was found, with 286 cutaneous leishmaniasis cases and 160
(35.9%) VL cases. Among the latter, 16 (10%) were VL/HIV-
coinfected patients and 20 (12.5%) had other types of immuno-
suppression [28].
In Italy, the Campania region has the highest VL incidence,
although HIV coinfection in this area is extremely rare. The regions
contributing historically with most of the VL/HIV cases in this
country were Sicily, Lombardy, and Latium, although leishmaniasis
transmission is progressing to the more industrialized north (Valle
d’Aosta, Lombardy, Venetto, etc.) where HIV is more prevalent.
Currently, coinfected cases from these areas have already been
reported, and careful surveillance is needed [29]. VL/HIV coin-
fection in the Maghreb seems to be a rare autochthonous problem
[3], and this has been confirmed in a recent review [30].
HAART has contributed to the decrease in the incidence of
VL/HIV cases in Europe, which has been observed since 1997 in
all countries except Portugal, where, for unknown reasons, 107
coinfected cases among 173 VL patients were found during the
period of 2000–2009 [31].
Visceral leishmaniasis and cutaneous leishmaniasis (CL) acquired
in the Mediterranean area in countries such as Greece, France,
Spain, Italy, Portugal, Turkey, and Croatia, which are considered
premier tourist attractions, have been imported to northern Euro-
pean countries [32–34]. Moreover, imported cases to the Mediter-
ranean region, mostly CL acquired by travelers to South and
Central America [32,35], have also been described.
Clinical Manifestations of Visceral Leishmaniasis
in HIV-Coinfected Patients
Typical manifestations of VL include fever, weight loss, hepato-
splenomegaly, and pancytopenia resulting from replication of
Leishmania amastigotes in macrophages mainly in the liver,
spleen, and bone marrow.
Typical features such as splenomegaly may be absent in VL/
HIV-coinfected patients [36], whereas atypical organ involvement,
such as of the lungs or gastrointestinal system, may be found.
Amyloid A (AA) amyloidosis leading to renal failure has been
associated with chronic VL in HIV patients [37–39].
In patients infected with HIV, impaired immune function may
favor the reactivation of latent Leishmania infections. Interactions
between both pathogens in host cells may influence their expression
and multiplication. Leishmaniasis can promote viral replication and
enhance progression to AIDS. Other factors such as a shift towards
a T helper 2 (Th2)-type specific response to Leishmania in patients
with HIV-1-induced T lymphocyte dysfunction could also explain
the severity of the infection and the atypical manifestations observed
in some of these patients (in immunocompetent patients, T helper 1
(Th1) cellular immune responses to Leishmania have been asso-
ciated with protection) [3,19,40].
Cutaneous involvement is infrequent in the context of Leishmania/
HIV coinfection. In HIV patients, VL caused by L. infantum has
been reported with simultaneous associated CL [41]. Other studies
mention possible visceralisation of the infection from CL, as cuta-
neous infection predated visceral involvement [38]. Mucocutane-
ous lesions caused by L. infantum have also been described in HIV-
positive patients [42]. Leishmania parasites have been detected in
biopsies obtained from VL/HIV-coinfected patients that were
performed to study other skin lesions, such as rheumatoid nodulosis
and Kaposi’s sarcoma [27,43]. In some cases, the detection of
Leishmania in cutaneous lesions led to the diagnosis of VL; how-
ever, the presence of the parasite in skin diseases in which it has
no known etiological role may represent passive presence due to
widespread dissemination in patients with compromised immune
systems [37,44]. Atypical disseminated cutaneous leishmaniasis
(with diffuse, nonulcerated, maculopapular lesions) following
visceral disease and post-kala-azar dermal leishmaniasis (PKDL)
caused by L. infantum (an infrequent association) has also been
described in HIV patients [45,46]. Posterior uveitis has been reported
in association with PKDL in a VL/HIV-coinfected patient on
monthly liposomal amphotericin B prophylactic therapy [46].
A large proportion of the general population in the Mediter-
ranean area have asymptomatic L. infantum infection, as detected
by positive skin tests, serology, or peripheral blood PCR. Therefore,
HIV-positive patients with asymptomatic L. infantum infection
may also be expected. In fact, although patients infected with HIV
have a high risk of developing symptomatic VL, several studies
highlight the considerable proportion of these patients who may be
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asymptomatic carriers (cryptic infection) of L. infantum infection. In
recent reports, around 10% and 17% of HIV+ individuals in
southern France and Spain, respectively, were diagnosed with
asymptomatic Leishmania infection by serology (western blot and
immunofluorescent antibody test) [47,48]. In another study in the
south of Spain, L. infantum kinetoplast DNA was amplified from
peripheral blood samples of around 30% of asymptomatic HIV-
infected patients [49]. An association between high HIV viral load
and high parasitemia has been reported, possibly related to an
increased risk of progressing to symptomatic disease, although
further studies are needed to establish this risk for symptomatic
disease in these patients [19].
Diagnostic Methods for Visceral Leishmaniasis in
HIV-Coinfected Patients
The techniques for diagnosing Leishmania infection in HIV
patients have not changed significantly in recent years, and the
currently applied serological tests are not considered accurate
methods for diagnosis because of limited sensitivity. According to a
recent meta-analysis in Europe, immunoblotting showed the best
performance, with 75%–91% sensitivity and 65%–94% specificity.
Nonetheless, the available evidence indicates that serological tests
should not be used to rule out VL in HIV-infected patients
(Table 1) [50]. The combined use of the direct agglutination test
(DAT) and the rK39-immunchromatographic test (rK39-ICT),
both rapid and user-friendly methods, has been shown to be a
suitable approach for VL diagnosis in Ethiopian HIV-positive
patients, reaching a sensitivity of 98% [51]. The use of these two
approaches for HIV-associated VL diagnosis in the Mediterranean
region has not been properly evaluated in large series of VL/HIV-
coinfected patients. A study in Italy using the rk39-ICT showed
100% sensitivity and specificity in 19 patients with confirmed VL,
but only three of them were HIV positive [52]. Given the wide use
and acceptance of DAT and rK39-ICT for VL diagnosis in other
endemic areas [53], these two tests should be evaluated in the
Mediterranean region to assess whether their use alone or in com-
bination may improve the serodiagnosis of VL/HIV coinfection in
this region.
The detection of Leishmania antigen in urine using the latex
agglutination test commercialized as KAtex initially appeared to
be a promising, noninvasive tool for VL diagnosis and treatment
follow-up. Its sensitivity in different studies in Europe, including
both HIV-positive and HIV-negative patients, ranged from 69%
to 100% [54,55], and a positive result after treatment was strongly
associated with relapse [54,56], even though this was not confirmed
in all studies [55]. However, decreased sensitivity and specificity in
large diagnostic series [Israel Cruz, personal experience at WHO
Collaborating Centre for Leishmaniasis, Madrid] has precluded a
more widespread use of this test in the diagnosis of VL/HIV
coinfection. Future research to improve the existing format would
be necessary to obtain a useful noninvasive tool for diagnosis and
treatment monitoring.
In recent years, peripheral blood-PCR analysis has been vali-
dated as a sensitive and specific tool to detect Leishmania parasites
in coinfected patients using a minimally invasive technique [5,50].
Therefore, whereas classical diagnostic methods, such as bone mar-
row aspirate culture and microscopy, are still in use, diagnosis in this
region is mainly based on the combination of the molecular
detection of parasite DNA in peripheral blood by PCR and serology
(even considering the low sensitivity of the latter). Bone marrow
aspirates are still a source for parasite detection by PCR because of
increased sensitivity when compared with peripheral blood analysis
[5]. Despite the widespread use of molecular diagnosis techniques
for leishmaniasis in Europe and the various existing guidelines and
algorithms for diagnosis in HIV patients, there is still a lack of
consensus, with each laboratory using its own methodology. Thus,
the development of common guidelines for diagnosis is needed.
The current challenge in the HAART era is to find accurate
markers for prediction and detection of relapses, as these still occur
despite the use of HAART. Some authors have proposed real-time
PCR as a suitable tool for monitoring the parasite load during
follow-up of coinfected patients and to predict the risk of relapses
after treatment [6,7,57]. Parasite loads in VL relapses vary in
different patients, as shown in several studies [6,7,57,58], suggesting
that other parameters should be taken into account. Cota et al. [59]
identified some predictors of VL relapse in HIV-infected patients,
such as the absence of an increase in CD4+ cells at follow-up, lack of
secondary prophylaxis, and a previous history of VL relapse, and
suggested that CD4+ counts below 100 cells/mL at the time of
primary VL diagnosis may also be a predictive factor for VL relapse.
These parameters and real-time PCR to assess parasite load are the
tools currently available for monitoring VL in HIV-infected patients
[6,7,57,58].
New markers to assess cure and help predict relapses are still
needed [1]. Pioneer studies by Moreno et al. [60] using lymphocyte
blastogenesis assays and T cell subpopulation determination in a
series of 17 VL HIV-infected Spanish patients indicated that the
ability to mount and maintain a specific T cell response against
Leishmania after treatment is necessary to decrease the risk of relapses.
In fact, Bourgeois et al. [61], studying a cohort of 27 French VL
HIV-infected patients, observed that a CD4 count ,200 cells/mL
was strongly associated with relapse episodes, regardless of use of
HAART therapy and/or secondary prophylaxis against Leishmania.
Future research should focus on the assessment of cytokine pro-
files in larger series of patients. In an endemic area in Brazil, Costa
et al. [62] found, in non-HIV patients, that following ex vivo
stimulation with Leishmania antigens, the lymphocyte proliferative
response and the interferon gamma (IFN-c) production by
lymphocyte cultures were higher in cured VL and asymptomatic
L. chagasi–infected individuals than in active VL patients and
healthy subjects from the same area. This would indicate a pro-
tective immune status. Cytokine release assays after ex vivo stim-
ulation of peripheral blood cells are currently an important area of
research in epidemiological studies assessing Leishmania exposure
[63–65], as well as in studies aiming to define the immunological
profile of VL patients and immune individuals [66]. A later study
Table 1. Estimated sensitivity and specificity of diagnostic
tests based on antibody detection for VL in HIV-infected
patients, using a random effects model and their respective
95% confidence intervals [50].
Diagnostic Test Sensitivity (%) 95% CI Specificity (%) 95% CI
Immunoblotting 84 75–91 82 65–94
DAT 81 61–95 90 66–100
ELISA 66 40–88 90 77–98
IFAT 51 43–58 93 81–99
PCR-blood 92 83–98 96 80–100
Antigen detection
in urine
85–100 - 96–100 -
Data for antigen detection in urine [56,55]. Abbreviations: CI, confidence
interval; ELISA, enzyme-linked immunosorbent assay; IFAT, indirect fluorescent
antibody test.
doi:10.1371/journal.pntd.0003021.t001
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in India by Gidwani et al. [64] found that patients with active VL
also presented a positive IFN-c response after stimulation with
Leishmania antigens. This surprising result indicated that the
assessment of IFN-c alone would not give an accurate clue to
identify immune individuals. In the same endemic area, Singh et
al. [66] used the same approach to assess IFN-c, tumor necrosis
factor alpha (TNF-a), and interleukin-10 (IL-10) cytokines and
indicated that IL-10 was only released by stimulated peripheral
blood cells of active VL patients. Thus, the simultaneous assess-
ment of IL-10 and IFN-c could reflect more aptly the immuno-
logical response that could distinguish between those with active
disease and cured or subclinically infected, immune individuals.
These studies could also be applied to the follow-up of HIV-
infected patients with VL in the Mediterranean Basin, but data are
currently lacking in coinfected patients.
Although a clinical practice guideline for VL/HIV diagnosis has
been published by the World Health Organization [1], there are
no specific guidelines for the European region. Therefore, the
methods for diagnosis and follow-up (to determine cure and to
predict relapses) vary considerably but are mainly based on culture
of buffy coat from peripheral blood, blood PCR, and bone marrow
aspirate microscopy and culture and/or bone marrow PCR.
Therapeutic and Prophylactic Strategies for
Visceral Leishmaniasis in HIV-Coinfected Patients
The management of VL/HIV-coinfected patients may be
complex. These patients generally have lower cure rates and higher
mortality rates than HIV-negative patients, more treatment failures,
toxicity and resistance to pentavalent antimonial compounds [67],
and more relapses, especially if CD4+ counts are ,200 cel/ml.
These factors reduce the pharmacological options because the
response to treatment also decreases after multiple relapses [59]. A
few clinical trials regarding the efficacy of treatment in coinfected
patients have been published. To date, there is no general consensus
on the drug of choice, dose, or duration or on the efficacy of com-
bined therapies and maintenance therapy as secondary prophylaxis.
Based on published studies on VL/HIV-coinfected patients in
the Mediterranean area, amphotericin B (deoxycholate, the lipid
formulation, or the liposomal formulation) would be the first-line
therapeutic option. Although the only clinical trials performed in
the Mediterranean region have been performed with amphotericin
B deoxycholate (AB) and amphotericin B lipid complex (ABLC),
currently the WHO and other international guidelines recom-
mend liposomal amphotericin B (LAB) as the first option because
of its safety profile and cure rates as reported in studies performed
in other geographical areas with other Leishmania species [68,69].
Antimonials have been compared with AB and ABLC and have
similar cure rates but more severe toxicity, so they should be
considered only as second-line drugs [10,11,67,70].
Experience with miltefosine is limited, and although initial cure
rates were favorable, almost all patients relapsed [71]. Experience
with other drugs such as pentamidine or paromomycin is limited
to clinical cases, and these are mainly administrated in combina-
tion with other drugs [72,73].
Many experts advocate for combined therapy among VL/HIV-
coinfected patients in order to increase efficacy, especially in those
patients with multiple relapses, and to decrease the emergence of
resistant parasites. However, data to assess the efficacy of antileish-
manial combination therapy in VL/HIV patients are insufficient,
and no clinical trials have been performed in the Mediterranean
area [3]. Only isolated cases of combination regimens with pent-
amidine and fluconazol, miltefosine and sodium stibogluconate
[72,74], allopurionol and meglumine antimoniate [75], or LAB
and the human recombinant granulocyte-macrophage colony-
stimulating factor (rhuGM-CSF) colony growth factor [76] have
been published with good results, but they are insufficient to
establish firm recommendations. Future research should probably
be focused on regimens based on the combination of LAB and
other second-line drugs such as miltefosine, paromomycin, or
pentamidine. In fact, the Drugs for Neglected Diseases Initiative
(DNDi) is performing a randomized clinical trial comparing LAB
alone versus LAB in combination with miltefosine in Ethiopian
VL/HIV-coinfected patients, but this has just started, and no data
are available yet. Treatment recommendations for VL/HIV-
coinfected patients in the Mediterranean and grades of evidence
based on the Infectious Diseases Society of America (IDSA) grade
classification [77,78] are summarized in Table 2.
Most available data on secondary prophylaxis after a treated
episode of VL in HIV-infected patients have been reported from
Europe, where zoonotic transmission of L. infantum occurs. Such
studies are mostly based on secondary prophylaxis with ABLC
[79] and LAB [80]. Other drugs used for secondary prophylaxis
but with less supporting evidence are pentavalent antimonials [81],
pentamidine [82–84], miltefosine [85], azole drugs [86,87], and
allopurinol, alone or in combination (Table 3) [88–90].
Table 2. Therapy for visceral leishmaniasis in HIV-coinfected patients in the Mediterranean area.
Treatment
Grade for VL/HIV in the Mediterranean
Basin Caused by L. infantum
Amphotericin B deoxycholate 20 mg/kg as 0.7 mg/kg/day IV for 28 days. BI
Amphotericin B lipid complex total dose 30 mg/kg as 3 mg/kg/day IV for 10 days BI
Liposomal amphotericin B total dose of 50 (40–60) mg/kg as 4 mg/kg/day IV on days 1–5, 10, 17, 14, 31, and 38 BIII
Meglumine antimoniate (IM or IV): 20 mg Sbv+/kg/d (without upper limit of 850 mg/d) for 28 d CI
Miltefosine: 100–150 mg/day po for 28 days CIII
Combination therapy: Liposomal amphotericin B+paromomycin or miltefosine No data
Evidence-based recommendation. Strength of recommendation: A = Good evidence to support a recommendation for use; B = Moderate evidence to support a
recommendation for use; C = Poor evidence to support a recommendation; D = Moderate evidence to support a recommendation against use; E = Good evidence to
support a recommendation against use.
Quality of evidence: I = Evidence from one or more randomized clinical trials; II = Evidence from one or more well-designed clinical trials, without randomization; from
cohort or case-controlled analytic studies (preferably from .1 center); from multiple time series; or from dramatic results from uncontrolled experiments; III = Evidence
from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees [77,78]. Abbreviations: IM, intramuscular; IV,
intravenous; po, per os.
doi:10.1371/journal.pntd.0003021.t002
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Most experts judge that once patients have recovered their
immune function with HAART and the VL is quiescent, pro-
phylaxis could be stopped when CD4+ count is maintained at .
200 cells/mL for more than 6 months [91,92].
The Impact of Highly Active Antiretroviral
Therapy on Visceral Leishmaniasis in
HIV-Coinfected Patients
The HAART-induced reconstitution of cellular immunity seems
to be the main determinant in reducing opportunistic infections in
HIV-positive individuals. However, several studies have shown
that HIV-1 protease inhibitors (PI) may exert antiparasitic effects
directly. This could be explained by the fact that proteases of certain
parasites could be an unspecific target for HIV-1 PI [93].
HAART in VL/HIV-coinfected patients in the Mediterranean
area has achieved a 50%–60% reduction in the VL incidence,
with higher survival rates and a reduction in relapse rates [9,25].
However, two novel entities have been described in association
with VL/HIV after the introduction of HAART in the Mediter-
ranean Basin. HAART may produce an immune reconstitution
inflammatory syndrome (IRIS) with AIDS-associated leishmaniasis
resembling PKDL due to L. infantum even many months or years
after the diagnosis of VL [94,95]. HAART may also lead to
asymptomatic carriers [6,19,49], and these may pose a risk for
transmission in areas where the sandfly vector is present [7].
Future Considerations
Currently, leishmaniasis is spreading northwards in endemic
regions, outbreaks are occurring in endemic areas, and foci of the
disease are appearing in previously nonendemic European countries
[96,97]. Thus, awareness about leishmaniasis should be increased
among health professionals [98]. Moreover, regional and interna-
tional VL control programs (including surveillance) within these
regions are needed.
For Leishmania/HIV-coinfected patients, serological tests have
a low sensitivity, and cross-reactions are possible [99]. Improved
antigen detection tests are of paramount importance for use as tests
of cure and to monitor relapses [56]. Considering the unfavourable
prognosis of coinfection and the high risk of relapses, development
of (bio) markers would be crucial in order to link the clinical out-
come and the parasitological status and establish better criteria of cure.
Recurrent relapses may select resistant clones that could con-
tribute to the spread of drug resistance, especially in anthroponotic
leishmaniasis settings [3]. Research should focus on the use of









N = 17, Spain Group 1 (N = 8): Amphotericin B lipid
complex (IV) 3 mg/kg/day every
21 days. Group 2 (N = 9): No treatment.
Follow-up for 12 months. 50% and
22.2% relapse-free, respectively.
Molina I et al. [80] N = 17, Spain All patients received for VL episode
liposomal amphotericin B 4 mg/kg/day
(IV) for 5 consecutive days followed by
one dose per week for 5 weeks.
Median follow-up time was 14
months (range 5–44 months).
Calculated probability of being
relapse-free was 89.7%, 79.1%, and
55.9% at 6, 12, and 36 months
follow-up, respectively.
Miltefosine Marques N et al. [85] N = 5, Portugal All patients received miltefosine
50 mg (po) 3 times a week.
Treatment was performed until
.250 CD4/mm3 and for a
minimum of 12 months (12–24).
Three patients were followed up
after miltefosine was discontinued
(8–28 months). All patients were
relapse-free.
Pentavalent Antimonials Ribera E et al. [81] N = 46, Spain Group 1 (N = 20): No treatment. Group 2
(N = 9): Allopurinol 300 mg/8 h (po).
Group 3 (N = 17): Pentavalent antimonials
850 mg (parenteral) once a month.
Patients were followed up until
relapse. 35%, 44%, and 82% were
relapse-free, respectively.
Pentamidine Pérez Molina JA
et al. [84]
N = 6, Spain Group 1 (N = 3): Pentamidine isethionate
(IV) 4 mg/kg every 2 weeks. Group 2
(N = 3): Pentamidine isethionate (IV)
every 4 weeks.
Average follow-up was 8 months
(3–12 months). One relapse in
group 2, 7 weeks after
pentamidine was stopped.
Patel TA et al. [83] N = 4, United Kingdom Patient 1 & 2: pentamidine (IV) 6 mg/kg
every 3 weeks. Patient 3 & 4:
pentamidine (IV) 6 mg/kg fortnightly.
Follow-up from 5 months to 4
years. All relapse-free during
follow-up.
Azoles Angarano G et al. [86] N = 5, Italy All received itraconazole 600 mg/day
(po) in two doses
Maintenance treatment from 6 to
24 months. All relapse-free during
follow-up except for one.
Combined Therapies Barragán P et al. [90] N = 1, Spain Itraconazole 400 mg/day (po) plus
miltefosine 150 mg/day with 1 month
on and 2 months off schedule.
19 months of treatment
relapse- free.
Torrus D et al. [89] N = 2, Spain Fluconazol 200 mg (po) plus allopurinol
300 (po) daily.
Follow-up at 9 and 11 months.
Both patients relapse-free
doi:10.1371/journal.pntd.0003021.t003
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combination therapy in these patients to reduce the number of
relapses, prevent resistance, and reduce toxicity, avoiding the use
of the highly cardiotoxic pentavalent antimonials.
There are no well-established criteria on which drug should be
used for secondary prophylaxis, and clinical trials in this regard are
necessary. Secondary prophylaxis with a drug different than that
used for treating the primary VL attack would be recommended to
minimize the risk of resistance spreading. However, these studies
may be difficult to perform given the low prevalence of coinfection
in Europe, and some conclusions may have to be extrapolated
from data obtained in other settings [38].
Specific preventive measures for VL among HIV patients in the
Mediterranean region have not been addressed. However, based
on the hypothesis of possible anthroponotic artificial transmission
by contaminated syringes, preventive measures focused on
avoiding needle sharing among intravenous drug users may
reduce transmission in the Mediterranean region [18]. Systematic
screening and primary prophylaxis for VL among HIV patients as
a preventive measure is not recommended in international
guidelines. However, this probably merits further exploration in
VL-endemic areas [100].
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